- Home
- DVAX vs NEXT Comparison
DVAX vs NEXT Comparison
Compare DVAX & NEXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- NEXT
- Stock Information
- Founded
- DVAX 1996
- NEXT 2010
- Country
- DVAX United States
- NEXT United States
- Employees
- DVAX N/A
- NEXT N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- NEXT Oil & Gas Production
- Sector
- DVAX Health Care
- NEXT Energy
- Exchange
- DVAX Nasdaq
- NEXT Nasdaq
- Market Cap
- DVAX 1.7B
- NEXT 1.9B
- IPO Year
- DVAX 2004
- NEXT N/A
- Fundamental
- Price
- DVAX $12.45
- NEXT $9.10
- Analyst Decision
- DVAX Buy
- NEXT Hold
- Analyst Count
- DVAX 2
- NEXT 1
- Target Price
- DVAX $23.00
- NEXT $9.00
- AVG Volume (30 Days)
- DVAX 1.8M
- NEXT 2.1M
- Earning Date
- DVAX 02-20-2025
- NEXT 03-10-2025
- Dividend Yield
- DVAX N/A
- NEXT N/A
- EPS Growth
- DVAX N/A
- NEXT N/A
- EPS
- DVAX 0.15
- NEXT N/A
- Revenue
- DVAX $260,810,000.00
- NEXT N/A
- Revenue This Year
- DVAX $21.64
- NEXT N/A
- Revenue Next Year
- DVAX $19.81
- NEXT N/A
- P/E Ratio
- DVAX $82.38
- NEXT N/A
- Revenue Growth
- DVAX N/A
- NEXT N/A
- 52 Week Low
- DVAX $9.74
- NEXT $4.27
- 52 Week High
- DVAX $14.30
- NEXT $9.37
- Technical
- Relative Strength Index (RSI)
- DVAX 41.74
- NEXT 74.64
- Support Level
- DVAX $12.27
- NEXT $7.95
- Resistance Level
- DVAX $12.74
- NEXT $8.06
- Average True Range (ATR)
- DVAX 0.35
- NEXT 0.47
- MACD
- DVAX -0.06
- NEXT 0.13
- Stochastic Oscillator
- DVAX 37.39
- NEXT 89.26
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About NEXT NextDecade Corporation
NextDecade Corp is a energy company predominantly engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The company provides a number of services depending on the individual needs of the customer. These include the supply and trade of LNG volumes, the creation of new natural gas infrastructure including pipeline and natural gas liquefaction facilities, treatment and processing of natural gas into LNG, as well as technical engineering and design services related to the development and execution of natural gas infrastructure, transporting, shipping and storage of LNG.